Table 4.
ART Regimen Detailsa
| Among Analysis Population | Among Participants on INSTI at Entry | ||||||
|---|---|---|---|---|---|---|---|
| Regimen Details | Specific Regimen | Total (N = 4500) | Non-INSTI- Containing Entry Regimen (N = 2652) | INSTI-Containing Entry Regimen (N = 1848) | Entry INSTI = DTG (N = 882) | Entry INSTI = EVG (N = 643) | Entry INSTI = Otherb (N = 323) |
| ART regimen (by class) | NRTI + NNRTI | 1638 (36%) | 1638 (62%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| NRTI + INSTI | 1437 (32%) | 0 (0%) | 1437 (78%) | 689 (78%) | 592 (92%) | 156 (48%) | |
| NRTI + PI | 930 (21%) | 930 (35%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| NRTI-sparing | 146 (3%) | 25 (1%) | 121 (7%) | 69 (8%) | 0 (0%) | 52 (16%) | |
| Other NRTI-containing | 349 (8%) | 59 (2%) | 290 (16%) | 124 (14%) | 51 (8%) | 115 (36%) | |
| Entry NRTI | TDF | 2574 (59%) | 1891 (72%) | 683 (40%) | 200 (25%) | 293 (46%) | 190 (70%) |
| ABC | 678 (16%) | 208 (8%) | 470 (27%) | 448 (55%) | 0 (0%) | 22 (8%) | |
| TAF | 668 (15%) | 182 (7%) | 486 (28%) | 107 (13%) | 350 (54%) | 29 (11%) | |
| ZDV | 261 (6%) | 255 (10%) | 6 (0%) | 3 (0%) | 0 (0%) | 3 (1%) | |
| Other NRTI | 173 (4%) | 91 (3%) | 82 (5%) | 55 (7%) | 0 (0%) | 27 (10%) | |
| Entry NNRTI | EFV | 1271 (70%) | 1261 (75%) | 10 (8%) | 0 (0%) | 0 (0%) | 10 (15%) |
| RPV | 337 (19%) | 291 (17%) | 46 (37%) | 43 (72%) | 0 (0%) | 3 (5%) | |
| NVP | 103 (6%) | 103 (6%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| ETR | 97 (5%) | 28 (2%) | 69 (55%) | 17 (28%) | 0 (0%) | 52 (80%) | |
| Entry PI | DRV | 655 (50%) | 377 (38%) | 278 (84%) | 130 (88%) | 44 (86%) | 104 (79%) |
| ATV | 529 (40%) | 493 (50%) | 36 (11%) | 13 (9%) | 7 (14%) | 16 (12%) | |
| LPV | 112 (8%) | 99 (10%) | 13 (4%) | 3 (2%) | 0 (0%) | 10 (8%) | |
| Other PI | 27 (2%) | 23 (2%) | 4 (1%) | 2 (1%) | 0 (0%) | 2 (2%) | |
Abbreviations: ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; EVG, elvitegravir; INSTI, integrase-strand transfer inhibitor; LPV, lopinavir; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse-transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
a
All statistics are calculated with data collected from participants. Entry PI does not include boosting agents.
b
“Other” INSTI includes participants on raltegravir or bictegravir.